研究等業績 - その他 - 羽渕 友則
-
ドナーから持ち込まれたレシピエント移植腎結石の臨床経過と対応
中島 志織, 井上 高光, 奈良 健平, 千葉 修治, 神田 壮平, 沼倉 一幸, 齋藤 満, 成田 伸太郎, 佐藤 滋, 羽渕 友則
日本尿路結石症学会誌 ( 日本尿路結石症学会 ) 17 ( 1 ) 55 - 55 2018年08月
-
irAE 転移性腎細胞癌に対するNivolumabの治療成績とirAE
沼倉 一幸, 堀川 洋平, 井上 高光, 奈良 健平, 神田 壮平, 齋藤 満, 成田 伸太郎, 黄 明国, 佐藤 滋, 下田 直威, 羽渕 友則
腎癌研究会会報 ( (一社)腎癌研究会 ) ( 48 ) 23 - 23 2018年07月
-
SunitinibおよびN-desethyl-sunitinibの血中濃度の測定による治療薬物モニタリングと治療効果に関する検討
沼倉 一幸, 藤山 信広, 鶴田 大, 前野 淳, 成田 伸太郎, 井上 高光, 佐藤 滋, 新岡 丈典, 三浦 昌朋, 羽渕 友則
腎癌研究会会報 ( (一社)腎癌研究会 ) ( 48 ) 91 - 91 2018年07月
-
分子標的薬時代の転移性腎癌における一次転移臓器別の予後解析
井上 高光, 高山 孝一朗, 喜早 祐介, 沼倉 一幸, 鶴田 大, 前野 淳, 齋藤 満, 成田 伸太郎, 佐藤 滋, 羽渕 友則
腎癌研究会会報 ( (一社)腎癌研究会 ) ( 48 ) 104 - 104 2018年07月
-
血管内皮関連遺伝子多型とaxitinibの臨床効果との関連
小泉 淳, 沼倉 一幸, 奈良 健平, 神田 壮平, 黄 明国, 齋藤 満, 成田 伸太郎, 井上 高光, 佐藤 滋, 羽渕 友則
腎癌研究会会報 ( (一社)腎癌研究会 ) ( 48 ) 32 - 32 2018年07月
-
転移性腎癌患者における1st-line Sunitinib療法とAxitinib療法とのアウトカムの比較検討
喜早 祐介, 井上 高光, 高山 孝一朗, 沼倉 一幸, 鶴田 大, 齋藤 満, 成田 伸太郎, 羽渕 友則
腎癌研究会会報 ( (一社)腎癌研究会 ) ( 48 ) 96 - 96 2018年07月
-
Okubo T.
Japanese Journal of Clinical Oncology ( Japanese Journal of Clinical Oncology ) 48 ( 6 ) 570 - 575 2018年06月
BACKGROUND: Salvage treatments for biochemical relapse (BCR) after radical prostatectomy (RP) have several problems in terms of indications or adverse events. We studied the possibility of 2 years of bicalutamide monotherapy for BCR after RP. METHODS: Patients who showed BCR (prostate-specific antigen (PSA) ≥ 0.2 ng/ml) after RP were recruited. Protocol treatment was planned as 2 years of bicalutamide (80 mg/day) followed by observation. Protocol treatment failure was defined as PSA re-elevation of ≥0.2 ng/ml, clinical progression, any other treatments, or discontinuation or restart of bicalutamide. Primary endpoint of this study is time to protocol treatment failure from initiation of bicalutamide. RESULTS: A total of 91 patients were registered between 2003 and 2009. Median age and PSA at initiating bicalutamide were 68 (range, 55-78) years and 0.32 (range, 0.19-7.91) ng/ml. Twenty-four (26.4%) patients could not complete 2 years of bicalutamide mainly due to progression of disease. Of the 91 patients, 2- and 5-year protocol treatment failure-free survivals were 74.6% and 33.0%, with a median follow-up of 76 (range, 11-118) months. Median time from initiating bicalutamide to treatment failure was 43 (95% confidence interval, 33-47) months. High-risk status at RP and time to BCR after RP < 6 months were significant predictors of second BCR. CONCLUSIONS: Two years of bicalutamide monotherapy should not be recommended as standard management for BCR after RP, but might be feasible for selected patients who do not have high-risk status at RP and short time to BCR.
-
ロボット支援腎部分切除術(RAPN);導入から応用まで ロボット支援腹腔鏡下腎部分切除術におけるデバイスの選択
井上 高光, 齋藤 満, 神田 壮平, 奈良 健平, 沼倉 一幸, 成田 伸太郎, 羽渕 友則
泌尿器外科 ( 医学図書出版(株) ) 31 ( 臨増 ) 681 - 684 2018年06月
-
奈良 健平, 成田 伸太郎, 沢石 由記夫, 小原 崇, 神田 壮平, 沼倉 一幸, 齋藤 満, 佐藤 滋, 羽渕 友則
日本小児泌尿器科学会雑誌 ( 日本小児泌尿器科学会 ) 27 ( 2 ) 287 - 287 2018年06月
-
本間 直子, 鶴田 大, 奈良 健平, 神田 壮平, 沼倉 一幸, 齋藤 満, 成田 伸太郎, 井上 高光, 佐藤 滋, 羽渕 友則
泌尿器外科 ( 医学図書出版(株) ) 31 ( 臨増 ) 808 - 808 2018年06月
-
奈良 健平, 成田 伸太郎, 神田 壮平, 沼倉 一幸, 鶴田 大, 齋藤 満, 井上 高光, 佐藤 滋, 羽渕 友則
泌尿器外科 ( 医学図書出版(株) ) 31 ( 臨増 ) 826 - 826 2018年06月
-
腎移植患者におけるタクロリムス変動係数と服薬アドヒアランス、拒絶反応との関連性
山本 竜平, 齋藤 満, 藤山 信弘, 奈良 健平, 神田 壮平, 沼倉 一幸, 鶴田 大, 成田 伸太郎, 井上 高光, 佐藤 滋, 羽渕 友則
泌尿器外科 ( 医学図書出版(株) ) 31 ( 臨増 ) 821 - 821 2018年06月
-
膀胱全摘除術を行った75歳以上の膀胱癌患者における補助化学療法の意義
小林 瑞貴, 沼倉 一幸, 神田 壮平, 鶴田 大, 齋藤 満, 成田 伸太郎, 井上 高光, 佐藤 滋, 羽渕 友則
泌尿器外科 ( 医学図書出版(株) ) 31 ( 臨増 ) 832 - 832 2018年06月
-
奈良 健平, 井上 高光, 神田 壮平, 沼倉 一幸, 鶴田 大, 齋藤 満, 成田 伸太郎, 佐藤 滋, 羽渕 友則
泌尿器外科 ( 医学図書出版(株) ) 31 ( 臨増 ) 836 - 836 2018年06月
-
Numakura K.
Oncotarget ( Oncotarget ) 9 ( 38 ) 25277 - 25284 2018年05月
In this study, we examined the association between the pharmacokinetics (PK) level of sunitinib malate (SU) and its metabolite N-desethyl-sunitinib (DSU) in terms of adverse events (AEs) and clinical outcomes in patients with metastatic renal cell carcinoma (mRCC). The PK of sunitinib (SU and DSU) was examined in 26 patients (20 men and 6 women) with mRCC. The associations between SU/DSU C0 and AE occurrence, best response rate, time to treatment failure, progression-free survival (PFS), and overall survival (OS) were investigated. Occurrence of grade 1 or higher hand-foot syndrome and thrombocytopenia (p = 0.002 and 0.024, respectively) was associated with a high concentration before morning intake (C0) level of SU. Low C0 levels of DSU were significantly associated with drug discontinuation due to disease progression (p = 0.035). Patients with DSU C0 level higher than 15.0 ng/mL showed a tendency toward increased PFS (61 weeks vs 12 weeks, p = 0.004) and OS (36 months vs 8 months, p = 0.040). The C0 level of SU and SU + DSU were not associated with prognosis. The higher level of C0 of SU may predict developing AEs and DSU C0 >15.0 ng/mL may lead to better prognosis of patients treated with sunitinib. PK of sunitinib may be useful for determining adequate dosages and prevention of severe AEs. Further studies are required to establish the utility of the PK of sunitinib in patients with mRCC.
-
Sato H.
BMC Urology ( BMC Urology ) 18 ( 1 ) 32 - 32 2018年05月
BACKGROUND: Less evidence is known about the role of early changes in serum biomarker after androgen deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC). Here we evaluated the impact of pre-treatment prognostic factors and early changes in serum biomarkers on prostate specific antigen (PSA) progression-free and overall survival rates in mHSPC. METHODS: We retrospectively reviewed the medical records of 60 mHSPC patients (median age 72 years) treated with ADT whose laboratory data at baseline and following 12 weeks were available. RESULTS: Forty-four patients (73%) had PSA progression and 27 patients (45.0%) died during a median follow-up of 34 months. The multivariable Cox hazard model demonstrated that a log-transformed baseline PSA level (p = 0.003) and an extent of bone disease (EOD) score of ≥3 (p = 0.004) were statistically associated with an increased risk for PSA progression whereas one unit increase in a log-transformed PSA change (baseline-12 weeks) was associated with a decreased risk for PSA progression (p = 0.004). For overall survival, a high level of alkaline phosphatase (ALP) at 12 weeks was associated with increased risk (p = 0.030) whereas a one-unit increase in the log-transformed PSA change was associated with decreased risk (p = 0.001). CONCLUSIONS: An increased level of PSA at baseline, or an EOD score of ≥3 may be a good predictor of PSA progression, and a high level of ALP at 12 weeks may be a risk predictor of death. A larger decline in PSA at 12 weeks from the baseline was associated with both PSA progression-free and overall survival time. Early changes in serum biomarkers may be useful in predicting poor outcomes in patients with mHSPC who are initially treated with ADT.
-
Komine N.
International Immunopharmacology ( International Immunopharmacology ) 58 57 - 63 2018年05月
The impact of CYP3A5 polymorphisms on clinical outcomes is controversial. The present study investigated the impact of CYP3A5 genetic differences on the development of interstitial fibrosis (IF) from 0 h to 1 year post-transplantation in biopsy sections from 96 living kidney recipients under the same target trough regimen of tacrolimus. The relationships between CYP3A5 polymorphisms and long-term graft function and death-censored graft survival were also examined. A quantitative analysis of IF was performed using computer-assisted imaging on virtual slides. Percent IF (%IF) in the cortical region at 0 h was defined as the baseline, and increases in the ratio of %IF 1 year post-transplantation were calculated. The relationships between CYP3A5 genetic differences and the development of IF, the incidence of clinical events, and the long-term function and death-censored survival of grafts were assessed. The mean increase in the ratio of %IF from 0 h to 1 year was 1.38 ± 0.74-fold. Despite therapeutic drug monitoring (TDM), trough levels of tacrolimus were lower in carriers with the CYP3A5*1 allele (expressers) than in those with the CTP3A5*3/*3 genotype (non-expressers) throughout the 1-year post-transplantation period. However, CYP3A5 genetic differences were not associated with the development of IF, any clinical events, or the long-term function and survival of grafts. The clinical impact of CYP3A5 genetic differences may be small under the current immunosuppressive regimen consisting of mycophenolate mofetil, steroids, basiliximab, and lower target trough levels of tacrolimus with suitable TDM in a low immunological risk population.
-
腹腔鏡下副腎摘除術を行ったクッシング症候群における術後腎機能とその予測因子の検討
松田 芳教, 沼倉 一幸, 成田 伸太郎, 井上 高光, 羽渕 友則
日本内分泌・甲状腺外科学会雑誌 ( 日本内分泌外科学会・日本甲状腺外科学会 ) 35 ( Suppl.1 ) S108 - S108 2018年05月
-
Igarashi R.
Medical Oncology ( Medical Oncology ) 35 ( 4 ) 51 - 51 2018年04月
Axitinib is a potent second-line molecular-targeted agent for metastatic renal cell carcinoma (mRCC). Axitinib pharmacokinetics and its relation with genetic polymorphisms were evaluated to predict the adverse events (AEs) and efficacy of axitinib. We analyzed 46 patients with mRCC who were treated with axitinib. The plasma axitinib level was measured at 0, 2, 4, 8, and 12 h after administration (C0, C2, C4, C8, and C12; ng/mL) on day 7 of the treatment. Genetic polymorphisms related to axitinib pharmacokinetics, including SLCO1B1, SLCO1B3, SLCO2B1, ABCB1, ABCG2, CYP2C19, CYP3A5, and UGT1A1, were analyzed. Axitinib C0 and AUC0-12 in patients with UGT1A1 poor metabolisers (*6/*6, *6/*28, and *28/*28; n = 10) were significantly higher than those in patients with UGT1A1 extensive metabolisers (*1/*1, *1/*6,*1/*28, and *27/*28; n = 36) (23.6 vs. 7.8 ng/mL, p = 0.030, and 441.3 vs. 217.1 ng h/mL, p = 0.007). The cutoff levels of C0 to predict ≥ G2 hypothyroidism and ≥ G2 anorexia were 6.6 and 7.1 ng/mL, respectively (p = 0.005 and p = 0.035). The overall survival (OS) in patients with C0 > 5 ng/mL was significantly better than that in patients with C0 < 5 ng/mL (p = 0.022). Genetic polymorphisms in UGT1A1 were significantly associated with the plasma axitinib level. The plasma axitinib level was significantly associated with the frequency of AEs and OS in patients with mRCC. No direct relationship was observed between UGT1A1 genotypes and the frequency of AEs or OS.
-
Significance of Serum N-glycan Profiling as a Diagnostic Biomarker in Urothelial Carcinoma
Oikawa M.
European Urology Focus ( European Urology Focus ) 4 ( 3 ) 405 - 411 2018年04月
BACKGROUND: The clinical diagnosis of urothelial carcinoma (UC) relies on invasive methods in patients with hematuria. Although more sensitive and noninvasive screening methods are required, a specific serum biomarker for UC is lacking. OBJECTIVE: To examine whether serum glycan-based biomarkers can be applied to UC detection. DESIGN, SETTING, AND PARTICIPANTS: Between April 1994 and June 2016, serum N-glycan concentrations were retrospectively measured in 212 patients with UC before treatment (UC group) and 212 pair-matched controls using glycoblotting and mass spectrometry. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: N-glycan levels were compared between the groups using receiver operating characteristic curves to select candidate N-glycans. We created an N-glycan score based on the combination of candidate N-glycans. The specificity and sensitivity of the candidate N-glycan score were evaluated using receiver operating characteristic curves. RESULTS AND LIMITATIONS: The N-glycan score was calculated using six N-glycans (m/z 1566, m/z 1687, m/z 1769, m/z 1871, m/z 2011, and m/z 2337) that were significantly associated with UC. The median N-glycan score was significantly higher in the UC group than in the pair-matched control group (5.0 vs 1.0, p<0.001). The N-glycan score correctly classified UC patients with a sensitivity, specificity, and area under the curve of 93%, 81%, and 0.95, respectively. The limitations of our study included its retrospective nature and nonclinical setting. CONCLUSIONS: Serum N-glycan content has the potential to be a specific and sensitive novel serum biomarker that may improve the accuracy of the detection for UC and reduce unnecessary invasive screening. Validation of this test in a large-scale prospective study is needed. PATIENT SUMMARY: Combination of serum N-glycan (N-glycan score) is a novel serum marker for urothelial carcinoma that is expressed by 93% of patients and thus is far more sensitive than classic urine cytology. Validation in a large patient cohort is needed.